MARKET

GWPH

GWPH

GW Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

218.80
-0.10
-0.05%
Opening 12:16 04/19 EDT
OPEN
218.76
PREV CLOSE
218.90
HIGH
219.00
LOW
218.54
VOLUME
176.32K
TURNOVER
--
52 WEEK HIGH
219.00
52 WEEK LOW
87.07
MARKET CAP
6.90B
P/E (TTM)
-117.9388
1D
5D
1M
3M
1Y
5Y
Real Brands Inc. (OTC US: RLBD) is a Major Squeeze Candidate in the Rejuvenated CBD Space (NASDAQ: GWPH) (NASDAQ: JAZZ) (NYSEAMERICAN: YCBD) NASDAQ: NEPT) (NYSE: TPB) (OTC US: MRMD)
Apr 19, 2021 (OTC PR WIRE via COMTEX) -- Real Brands Inc (OTCMKTS:RLBD) is an emerging player on the rejuvenating CBD stock landscape, and one that may...
OTC · 3h ago
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15)
Benzinga · 3d ago
Cannabis Beverage Market 2027: Find Out Top Impacting Factor Of Market Growth By Opportunity And Industry Players
Apr 16, 2021 (Market Insight Reports) -- Cannabis beveragesincludes different types of alcoholic and non-alcoholic beverages which are infused with cannabis...
Market Insight Reports · 3d ago
Improving Quality of THC-Based Medications Proving to be Lucrative Path Cannabis Companies
Financial News Media · 4d ago
Why Real Brands Inc (OTC US: RLBD) is Tailor Made for CBD Boom 2.0 (NASDAQ: GWPH) NASDAQ: JAZZ) (NYSEAMERICAN: YCBD) (NASDAQ: NEPT) (NYSE: TPB) (OTC US: MRMD)
Apr 14, 2021 (OTC PR WIRE via COMTEX) -- Real Brands Inc (OTCMKTS:RLBD) could be perfectly positioned to rise as one of the emerging winners in CBD Boom 2.0....
OTC · 5d ago
JAZZ's Xywav sNDA for Hypersomnia Gets FDA Priority Review
Zacks.com · 6d ago
BRIEF-GW Pharmaceuticals PLC Says Nabiximols Data Show Efficacy And Safety Results In Patients With Spasticity Associated With Multiple Sclerosis
reuters.com · 6d ago
GW Pharmaceuticals And US Subsidiary Greenwich Biosciences To Present Data At 2021 American Academy Of Neurology Annual Meeting Apr. 17-22
GW Pharmaceuticals plc (NASDAQ:GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that the
Benzinga · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GWPH. Analyze the recent business situations of GW Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GWPH stock price target is 204.90 with a high estimate of 220.00 and a low estimate of 125.00.
EPS
Institutional Holdings
Institutions: 472
Institutional Holdings: 29.31M
% Owned: 92.93%
Shares Outstanding: 31.53M
TypeInstitutionsShares
Increased
63
810.13K
New
42
1.34M
Decreased
79
1.78M
Sold Out
41
911.70K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.94%
Pharmaceuticals & Medical Research
-0.30%
Key Executives
Chairman/Executive Director
Geoffrey Guy
Chief Executive Officer/Executive Director
Justin Gover
Chief Financial Officer
Scott Giacobello
Chief Operating Officer
Christopher Tovey
Managing Director/Secretary
Adam George
Other
Darren Cline
Other
Volker Knappertz
Other
Douglas Snyder
Other
Doug Snyder
Independent Director
David Gryska
Non-Executive Independent Director
Cabot Brown
Non-Executive Independent Director
Catherine Mackey
Non-Executive Independent Director
James Noble
Non-Executive Independent Director
Alicia Secor
Non-Executive Independent Director
William Waldegrave
No Data
  • All
  • Financials
  • Insiders
More
About GWPH
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company is also focused on developing its pharmaceutical product pipelines, which includes Epidiolex for the treatment of Tuberous Sclerosis Complex and RETT Syndrome.

Webull offers kinds of GW Pharmaceuticals PLC- ADR stock information, including NASDAQ:GWPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GWPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GWPH stock methods without spending real money on the virtual paper trading platform.